LAVA Therapeutics N.V. (LVTX)

NASDAQ: LVTX · IEX Real-Time Price · USD
0.08 (2.38%)
At close: May 20, 2022 4:00 PM
-0.05 (-1.45%)
After-hours:May 20, 2022 4:00 PM EDT

Company Description

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.

The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.

Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.

The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies.

LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use.

The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LAVA Therapeutics N.V.
CountryUnited States
IPO DateMar 25, 2021
SectorHealth Care

Contact Details

Yalelaan 60
Utrecht 3584 CM
Phone31 630 00 30 35

Stock Details

Ticker SymbolLVTX
Fiscal YearJanuary - December
Reporting CurrencyEUR
IPO Price$15.00
CIK Code1840748

Key Executives

Stephen Allen Hurly M.B.A., M.Sc.Chief Executive Officer and Executive Director
Peter RosVice President of Finance
Dr. Hans van der Vliet M.D., Ph.D.Chief Scientific Officer
Amy Garabedian J.D.General Counsel and Corporate Secretary
Wouter van HunnikVice President and Head of Human Resources
Dr. Benjamin Winograd M.D., Ph.D.Chief Medical Officer
Dr. Ton Adang Ph.D.Chief Development Officer
Dr. Paul W. H. I. Parren Ph.D.Executive Vice President, Head of Research & Development and MD

Latest SEC Filings

Apr 22, 2022EFFECTNotice of Effectiveness
Apr 12, 2022F-3Registration statement by foreign private issuers
Mar 28, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 24, 202220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]
Feb 14, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Jan 7, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 15, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Oct 13, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Aug 16, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
May 28, 2021S-8Securities to be offered to employees in employee benefit plans
View All SEC Filings